Merus N.V. (MRUS)

Market Cap	2.61B
Revenue (ttm)	43.95M
Net Income (ttm)	-154.94M
Shares Out	57.88M
EPS (ttm)	-3.00
PE Ratio	n/a
Forward PE	n/a
Dividend	n/a
Ex-Dividend Date	n/a

Volume	819,061
Open	44.66
Previous Close	44.93
Day's Range	44.00 - 45.84
52-Week Range	18.21 - 52.04
Beta	1.11
Analysts	Strong Buy
Price Target	55.22 (+22.52%)
Earnings Date	May 10, 2024

About MRUS

Merus N.V., a clinical-stage immuno-oncology company, engages in the development of antibody therapeutics in the Netherlands. Its bispecific antibody candidate pipeline includes Zenocutuzumab (MCLA-128), which is in a phase 2 clinical trials for the treatment of patients with metastatic breast cancer and castration-resistant prostate cancer, as well as in Phase 1/2 clinical trials for the treatment of solid tumors that harbor Neuregulin 1. The company is also developing MCLA-158, which is in a phase I clinical trial for the treatment of solid t...

• Industry: Biotechnology
• Sector: Healthcare
• IPO Date: May 19, 2016
• Employees: 229
• Stock Exchange: NASDAQ
• Ticker Symbol: MRUS

Financial Performance

In 2023, Merus's revenue was $43.95 million, an increase of 5.68% compared to the previous year's $41.59 million. Losses were -$154.94 million, 18.1% more than in 2022.

Analyst Forecast

According to 10 analysts, the average rating for MRUS stock is "Strong Buy." The 12-month stock price forecast is $55.22, which is an increase of 22.52% from the latest price.

Price Target

$55.22

(22.52% upside)

Analyst Consensus: Strong Buy